Lucid Diagnostics (NASDAQ:LUCD) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Lucid Diagnostics (NASDAQ:LUCD) was upgraded from a "strong sell" to a "hold" rating by Wall Street Zen, reflecting a shift in analyst sentiment.
• Other analysts have issued varying ratings, with Ascendiant Capital Markets setting a price target increase to $7.75 and Needham & Company maintaining a $3.00 target price.
• The stock has experienced recent gains, opening at $1.02, with a twelve-month trading range between a low of $0.73 and a high of $1.80.

Wall Street Zen upgraded shares of Lucid Diagnostics (NASDAQ:LUCD - Free Report) from a strong sell rating to a hold rating in a report issued on Saturday.

Other equities research analysts also recently issued reports about the company. Ascendiant Capital Markets upped their target price on Lucid Diagnostics from $7.50 to $7.75 and gave the company a "buy" rating in a report on Friday, June 6th. Needham & Company LLC reissued a "buy" rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $2.00 price objective on shares of Lucid Diagnostics in a research note on Thursday, May 15th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $3.55.

Lucid Diagnostics Stock Performance

Lucid Diagnostics stock traded down $0.0210 during mid-day trading on Friday, reaching $0.9990. 477,485 shares of the company were exchanged, compared to its average volume of 982,610. The firm has a market cap of $108.37 million, a PE ratio of -0.84 and a beta of 1.21. Lucid Diagnostics has a twelve month low of $0.73 and a twelve month high of $1.80. The firm's 50-day simple moving average is $1.12 and its two-hundred day simple moving average is $1.27.

Institutional Investors Weigh In On Lucid Diagnostics

A number of large investors have recently added to or reduced their stakes in LUCD. Quadrature Capital Ltd bought a new position in Lucid Diagnostics during the 2nd quarter worth $29,000. Berkshire Asset Management LLC PA bought a new stake in shares of Lucid Diagnostics in the 1st quarter worth approximately $30,000. Traphagen Investment Advisors LLC bought a new stake in Lucid Diagnostics during the 2nd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. bought a new stake in Lucid Diagnostics during the 1st quarter valued at $37,000. Finally, JPMorgan Chase & Co. raised its holdings in Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company's stock valued at $38,000 after acquiring an additional 32,672 shares during the period. Institutional investors and hedge funds own 74.01% of the company's stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.